Clearside Biomedical, Inc. announced that its Chief Medical Officer and Chief Development Officer, Thomas A. Ciulla, M.D., M.B.A., will transition to the role of Chief Medical Advisor-Retina for Clearside and step down from his full-time position, effective February 17, 2023. In his new advisory capacity, Dr. Ciulla will chair the Company's Scientific Advisory Board (SAB), sharing his medical expertise as a practicing retinal specialist and providing counsel on Clearside's ODYSSEY Phase 2b clinical trial and other suprachoroidal development programs.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.22 USD | +2.52% | -12.86% | +4.27% |
13/05 | HC Wainwright Adjusts Price Target on Clearside Biomedical to $5 From $6, Keeps Buy Rating | MT |
09/05 | Transcript : Clearside Biomedical, Inc., Q1 2024 Earnings Call, May 09, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.27% | 91.17M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- CLSD Stock
- News Clearside Biomedical, Inc.
- Clearside Biomedical, Inc. Executive Changes, Effective February 17, 2023